Pumitamig (BNT327/BMS986545) plus chemotherapy delivered high response rates in ROSETTA Lung-02, a phase 2 study of first-line non–small cell lung cancer presented at the 2026 ASCO Annual Meeting. Across 40 patients, the regimen showed an unconfirmed overall response rate of 72.5% and a confirmed ORR of 62.5%, with no new safety signals. The results were consistent across histologies and at different PD-L1 levels, with the safety profile marked by limited grade 3 events and no grade 4 or 5 toxicities reported. The study design and reported responses position the combination for further development in a setting where treatment outcomes remain strongly tied to biomarker and regimen selection. For investors and competitors, the key takeaway is the magnitude of confirmed responses at an early stage, paired with a manageable toxicity picture, supporting escalation into later-stage testing considerations.